The Aldo-Keto Reductase Akr1b7 Gene Is a Common Transcriptional Target of Xenobiotic Receptors Pregnan X Receptor and Constitutive Androstan Receptor

Ming-Jie Liu, Yuki Takahashi, Taira Wada, Jinhan He, Jie Gao, Yanan Tian, Song Li, and Wen Xie

Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania (M.-J.L., Y.T., T.W., J.H., J.G., S.L., W.X.); Department of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, Texas (Y.T.); and Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (W.X.)

Received May 1, 2009; accepted June 19, 2009

ABSTRACT

Aldo-keto reductase (AKR) family 1, member 7 (Akr1b7), a member of the AKR superfamily, has been suggested to play an important role in the detoxification of lipid peroxidation by-products. The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are xenosensors postulated to alleviate xen- and endobiotic chemical insults. In this study, we show that the mouse Akr1b7 is a shared transcriptional target of PXR and CAR in the liver and intestine. Treatment of wild-type mice with the PXR agonist pregnenolone-16α-carboxonitrile (PCN) activated Akr1b7 gene expression, whereas the effect was abrogated in PXR(-/-) mice. Similarly, the activation of Akr1b7 gene expression by the CAR agonist 1,4-bis[2-(3,5-dichlorpyridyloxyl)]-benzene, seen in wild-type mice, was abolished in CAR(-/-) mice. The promoter of Akr1b7 gene was activated by PXR and CAR, and this activation was achieved through the binding of PXR-retinoid X receptor (RXR) or CAR-RXR heterodimers to direct repeat-4 type nuclear receptor-binding sites found in the Akr1b7 gene promoter. At the functional level, treatment with PCN in wild-type mice, but not PXR(-/-) mice, led to a decreased intestinal accumulation of malondialdehyde, a biomarker of lipid peroxidation. The regulation of Akr1b7 by PXR was independent of the liver X receptor (LXR), another nuclear receptor known to regulate this AKR isoform. Because a major function of Akr1b7 is to detoxify lipid peroxidation, the PXR-, CAR-, and LXR-controlled regulatory network of Akr1b7 may have contributed to alleviate toxicity associated with lipid peroxidation.

The aldo-keto reductase (AKR) superfamily of genes encodes NAD(P)H-linked oxidoreductases. AKRs play an important role in the detoxification of harmful aldehydes and ketones generated from exogenous and endogenous toxicants and those produced from the breakdown of lipid peroxides. AKRs reduce aldehydes and ketones to their respective alcohols (Penning and Drury, 2007). Among AKR isoforms, the mouse Akr1b7 is highly expressed in vas deferens and adrenal gland, in which its sustained expression is dependent on androgen and adrenocorticotropic hormone, respectively (Lau et al., 1995). It is interesting that Akr1b7 null mice were found to be viable and have no obvious defect in reproduction (Baumann et al., 2007). Besides the steroidogenic tissues, Akr1b7 is also expressed in mouse kidney, eye, intestine, and, at a lower level, in liver (Lau et al., 1995).

One of the major functions of Akr1b7 is to detoxify lipid peroxidation. Lipid peroxidation refers to the oxidative deterioration of lipids containing carbon-carbon double bonds, thereby generating toxic aldehyde and ketone products, called lipid peroxidation reaction products. These products react covalently with membrane lipids, proteins, and DNA, leading to cytotoxicity and genotoxicity (Keshav et al., 2000). The aldehyde- and ketone-derived lipid peroxidation products are removed through the activity of AKRs.

ACKNOWLEDGMENTS

This study was supported in part by the National Institutes of Health National Cancer Institute [Grant CA107011] and the National Institutes of Health National Institute of Environmental Health Sciences [Grant ES014626]. Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org.


ABBREVIATIONS: AKR, aldo-keto reductase; PUFA, polyunsaturated fatty acid; MDA, malondialdehyde; PXR, pregnane X receptor; CAR, constitutive androstan receptor; RXR, retinoid X receptor; DR, direct repeat; LXR, liver X receptor; DKO, double knockout; PCN, pregnenolone-16α-carbonitrile; GW3965, 3-[3-{N-[2-chloro-3-trifluoromethyl]benzyl}-(2,2-diphenylethylnyl)aminopropyl]oxy]phenylacetic acid hydrochloride; FABP, fatty acid-binding protein; VP, viral protein 16; TCPOBOP, 1,4-bis[2-(3,5-dichlorpyridyloxyl)]-benzene; PCR, polymerase chain reaction; ChIP, chromatin immunoprecipitation; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; bp, base pair(s); PEI, polyethylenimine; DMEM, Dulbecco’s modified Eagle’s medium; EMSA, electrophoretic mobility shift assay; DMSO, dimethyl sulfoxide; kb, kilobase(s); LG268, 6-[[1,3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopropyl]pyridine-3-carboxylic acid; T0901317, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-[(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide.
especially those derived from polyunsaturated fatty acids (PUFAs). The peroxidation process proceeds by a free radical chain reaction, resulting in the production of many reactive aldehydes, among which the trans-4-hydroxy-2-nonenal was recognized as having the greatest toxic and harmful potential (Schneider et al., 2008). All unsaturated aldehydes may undergo further changes by autooxidation, leading to the production of other volatile derivatives, such as malondialdehyde (MDA). Akr1b7 has a preference for the by-products of lipid peroxidation as its substrates. These include trans-4-hydroxy-2-nonenal (Schneider et al., 2008) and isocaproaldehyde, another highly toxic lipid by-product generated during steriodogenesis (Lefrançois-Martínez et al., 1999).

The xenobiotic nuclear receptors, including pregnane X receptor (PXR; NR1I2) (Blumberg et al., 1998; Kliewer et al., 1998) and constitutive androstane receptor (CAR; NR1I3) (Honkakoski et al., 1998; Wei et al., 2000), were postulated to play an essential role in the detoxification of xenobiotic and endobiotic toxicants. The detoxifying effect of PXR and CAR is achieved through the coordinate transcriptional regulation of phase I and phase II enzymes, as well as drug transporters (for reviews, see Wilson and Kliewer, 2002; Timsit and Negishi, 2007). PXR and CAR regulate gene expression by heterodimerization with the retinoic acid receptor (RXR) and the binding of the PXR-RXR or CAR-RXR heterodimers to specific response elements termed PXR response elements or CAR response elements (also called phenobarbital response elements) that contain a hexanucleotide direct repeat separated by three or four nucleotides (DR-3 or DR-4) (Honkakoski et al., 1998). In addition to its function in xenobiotic detoxification, PXR has also been implicated in many other endobiotic functions, ranging from bile acid detoxification and cholestatic prevention (Staudinger et al., 2001; Xie et al., 2001) to bilirubin detoxification and clearance, adrenal steroid homeostasis and drug-hormone interactions (Zhai et al., 2007), lipid metabolism (for review, see Handschin and Meyer, 2005; Zhou et al., 2006b; Nakamura et al., 2007), inflammation and inflammatory bowel disease (Langmann et al., 2004; Dring et al., 2006; Zhou et al., 2006a; Shah et al., 2007), bone homeostasis (Pascuzzi et al., 2005), and retinoid acid metabolism (for review, see Zhang et al., 2008; Wang et al., 2008). Compared with its sister PXR, CAR exhibits many overlapping, yet distinct, functions (Timsit and Negishi, 2007). The liver X receptor (LXR), another nuclear hormone receptor, has been shown to regulate Akr1b7 (Volle et al., 2004). However, there has been no report on the role of PXR or CAR in the regulation of AKRs and detoxification of lipid peroxidation.

In this report, we show that Akr1b7 is a probable transcriptional target of PXR and CAR, suggesting a novel role for xenobiotic receptors in the detoxification of lipid peroxidation. The regulatory network of Akr1b7 controlled by PXR, CAR, and LXR may provide a complex and fail-safe system in preventing toxicity associated with lipid peroxidation.

**Materials and Methods**

**Animals and Drug Treatment.** The PXR null [PXR(−/−)] (Xie et al., 2000), CAR null [CAR(−/−)] (Wei et al., 2000), LXRα and β double-knockout (LXR DKO) (Peet et al., 1998), and fatty acid-binding protein (FABP)-VP-PXR transgenic (Gong et al., 2006) mice in C57BL/6J and SvJ129 mixed background have been described previously. Mice were housed in a pathogen-free animal facility under a standard 12-h light/dark cycle with free access to water and food. Age- and sex-matched 8- to 10-week-old mice were used for all the experiments. To activate PXR, mice received two (for gene expression analysis) or four (for lipid peroxidation analysis) daily intraperitoneal injections of PCN (100 mg/kg) and were sacrificed 4 h after the last dose. To activate LXR, mice received daily gavages of GW3965 (20 mg/kg) for 5 days and were sacrificed 24 h after the last dose. To activate CAR, mice received a single intraperitoneal injection of TCPOBOP (1 mg/kg) and were sacrificed 7 days after the injection. PCN and TCPOBOP were purchased from Sigma-Aldrich (St. Louis, MO). GW3965 was synthesized in-house following the scheme in Zhou et al. (2008). The use of mice in this study has complied with all the relevant federal guidelines and institutional policies.

**Real-Time Reverse Transcription-PCR.** Total RNA was isolated by using TRIzol reagent (Invitrogen, Carlsbad, CA). Reverse transcription was performed by using iScript cDNA synthesis kit from Bio-Rad Laboratories (Hercules, CA). Real-time PCR was performed with the 7300 real-time PCR system (Applied Biosystems, Foster City, CA) by using the SYBR Green reagents (Applied Biosystems). All the data were normalized against the mouse cyclophilin gene. The primer sequences of Akr1b7 are as follows: forward, 5′-CCCTCACCGCATACAGGAGAA-3′ and reverse, 5′-GCCATGTCCTCTCTCACTCAA-3′ (Volle et al., 2004). Other real-time PCR primers are as follows: Akr1a4 forward, 5′-GCTTAGATGCGAGGTCGTTCACGC-3′ and reverse, 5′-AGACATCTCGGGACCCCTCT-3′; Akr1b8 forward, 5′-CCTCAACCGAGAAACTGTA-3′ and reverse, 5′-CAGCTGTCCTCTCGATGGTGA-3′; and Akr7a5 forward, 5′-ATCAGGGGCAAGTTGTTG-3′ and reverse, 5′-CAGAAAGTGTTGTAGGCCGTAG-3′.

**Northern Blot Analysis.** The Akr1b7 cDNA probe was amplified from PCR mouse liver cDNA by using the forward primer, 5′-CAATGGAATGAGGTTGGAG-3′ and reverse primer, 5′-CCTACTCAACTGAATGTCGTA-3′. The 3′-end of the probe was synthesized using the 5′-end of the cDNA as template. The probe was labeled with [γ-32P]ATP by using T4 polynucleotide kinase. The probe was hybridized to Northern blots using a technique similar to that of Ogawa et al. (2000).

**Plasmid Constructs and Transfection Assays.** The 5′-regulatory sequence (−1972 bp to −4 bp) of the mouse Akr1b7 gene was cloned by PCR using the following pair of oligonucleotides: forward primer, 5′-GTTAACACATTACATGTCGAGGC-3′ (engineered with KpnI site) and reverse primer, 5′-CTCGAAGCTTTGACAGATGGAATGG-3′ (engineered with XhoI site). The design of oligonucleotides was based on mouse genomic sequences deposited in GenBank (accession NC_000072). The mouse liver genomic DNA was used as the PCR template. The PCR-amplified fragments were cloned into the pGL-3 basic vector from Promega (Madison, WI). Site-directed mutagenesis was performed by the PCR overextention method, and the mutations were confirmed by DNA sequencing.

Transient transfection was performed in HepG2 cells seeded in 48-well plates with polyethylenimine (PEI) polymer as the transfection reagent (Zhou et al., 2006). For each well, the plasmid-PEI complexes were formed by mixing 0.1 μg of expression vector for each nuclear receptor, 0.3 μg of reporter plasmid, 0.1 μg of β-galactosidase plasmid, and 0.5 μg of PEI at room temperature for 20 min in a total volume of 100 μl of serum-free Dulbecco’s modified Eagle’s medium (DMEM). The DNA-PEI complexes were then diluted with 2 ml of DMEM and applied at 200 μl per well. After 12 h of incubation, the transfection medium was replaced with DMEM containing 10% fetal bovine serum with the appropriate solvent or ligands. Cells were lysed and assayed for luciferase and β-galactosidase after 24 h of drug treatment.

**Identification of the Putative PXR/CAR Response Elements and Electrophoretic Mobility Shift Assay.** The promoter sequence analysis was performed by using the web-based software NUBIScan version 2.0 (http://www.nubiscan.unibas.ch/). The puta-
response elements were then analyzed for receptor binding by EMSA. For the EMSA assay, receptor proteins were prepared by using the in vitro TnT quick-coupled transcription/translation system (Promega). The nucleotide probes were labeled with [32P]dCTP by Klenow fill-in method. The binding reactions were performed at room temperature for 20 min (Wada et al., 2008). Protein-DNA complexes were resolved by vertical electrophoresis through 5% polyacrylamide gel in 0.5× Tris borate-EDTA at 4°C for 1.5 h. The gel was then dried and processed for autoradiography. The probe sequences are labeled in the figure. Unlabeled competitor DNAs (50–100×) were used for the parallel competition experiments.

**Chromatin Immunoprecipitation Assay.** The ChIP assay was performed essentially as described previously (Wada et al., 2008). In brief, primary mouse hepatocytes were prepared from wild-type mice by the collagenase perfusion method. Cells were treated with solvent (DMSO) or PCN (10 μM) for 24 h before formaldehyde cross-linking. Cell lysates were incubated overnight with 1 μg of anti-PXR antibody from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) at 4°C. Parallel samples were incubated with normal IgG as a negative control. The following PCR primers were used: Akr1b7 forward, 5'-ATATCCACTCTCCGGCGGAA-3' and Akr1b7 reverse, 5'-GGGCAAACAGACAGGGGA-3'. The PCR primers for the positive control Cd36 gene (Zhou et al., 2006) and negative control Cyp7b1 gene (Wada et al., 2008) were described previously.

**Intestinal MDA Measurement.** Freshly dissected mouse small intestine samples were homogenized on ice in KCl (150 mM) solution (1 g of wet tissue in 9 ml of KCl) using a Polytron homogenizer. For each assay, 100 μl of the supernatant was incubated with 900 μl of reaction buffer containing 0.67% thiobarbituric acid. This mixture was incubated at 98°C for 1 h and then centrifuged at 12,000 rpm for 20 min at 4°C. The absorbance of the supernatant was measured at 532 nm using a spectrophotometer. The absorbance was converted to nanomoles of MDA from a standard curve generated with 1,1,3,3-tetramethoxypropane.

**Western Blot Analysis.** Duodenum was collected from mice and homogenized in lysis buffer (50 mM Tris, pH 7.4, 1% Nonidet P40, 0.25% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM NaF, and 0.2% protease inhibitor cocktail from Sigma-Aldrich). The lysates were centrifuged at 13,000g for 20 min at 4°C, and the supernatants were collected. The protein concentrations in the supernatants were measured. Equal amounts of lysate proteins were resolved by 10% SDS-polyacrylamide gel electrophoresis gel, and then transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline/Tween 20 at room temperature for 1 h. Akr1b7 protein was detected by a primary polyclonal antibody against Akr1b7 (1:500; Santa Cruz Biotechnology, Inc.) and a secondary peroxidase-conjugated donkey anti-goat IgG antibody (1:5000; Cell Signaling Technology Inc., Danvers, MA). Protein signals were detected with the enhanced chemiluminescence reagents from GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK).

**Statistical Analysis.** Results are expressed as means ± S.D. Statistical analysis was performed using the unpaired Student’s t test for comparison between two groups.

**Results**

**Activation of PXR Induced the Expression of Akr1b7 in Vivo.** As shown in Fig. 1, treatment of wild-type mice with the PXR agonist PCN for 28 h induced the mRNA expression of Akr1b7 in the liver and small intestine, as determined by Northern blot analysis (Fig. 1A). Cyp3a11, a known PXR target gene, was included as a positive control for PXR activation. A similar Akr1b7 gene activation was observed in mice treated with PCN for 52 h (data not shown). The induction of intestinal Akr1b7 protein expression by PCN was also confirmed by Western blot analysis (Fig. 1B). The effect of PCN on Akr gene expression seemed to be isofrom-specific, because the expression of Akr1a4, -1b8, and -7a5 in the same animals was not significantly altered (Fig. 1C). The PCN effect on Akr1b7 gene expression was abolished in PXR(-/-) mice (Xie et al., 2000) (Fig. 1D), demonstrating that PXR is the bona fide mediator for the PCN effect. We have reported previously the creation of FABP-VP-PXR transgenic mice in which a constitutively activated human PXR (VP-PXR) was expressed in the liver and intestine under the control of the rat FABP gene promoter (Gong et al., 2006). Figure 1E shows
that the Akr1b7 gene activation was also observed in FABP-VP-PXR transgenic mice, although the magnitude of gene regulation seemed to be not as dramatic as that in the PCN-treated wild-type mice. In the same FABP-VP-PXR transgenic mice, the expression of Cyp3a11 was induced in both the liver and intestine (Gong et al., 2006). It is interesting that we found that the basal and PXR-inducible expression of Akr1b7 was higher in the intestine than that in the liver in both the pharmacological and genetic models of PXR activation. These results strongly suggest that Akr1b7 is a transcriptional target of PXR.

**Activation of CAR Induced the Expression of Akr1b7 in Vivo.** We found that treatment of wild-type mice with the CAR agonist TCPOBOP also induced the mRNA expression of Akr1b7 in the liver (Fig. 2A) and small intestine (Fig. 2B). Cyp2b10, a prototypical CAR target gene, was included as a positive control for CAR activation. The TCPOBOP effect on Akr1b7 gene expression in the liver (Fig. 2C) and small intestine (Fig. 2D) was abolished in CAR(−/−) mice (Wei et al., 2000), suggesting that Akr1b7 is also under the positive control of CAR. There was an additive induction of Akr1b7 mRNA expression in mice treated with both PCN and TCPOBOP (Fig. 2E).

**The Akr1b7 Gene Promoter Was Activated by PXR and CAR and Identification of the Response Element in the Promoter Region of Akr1b7 That Binds to Both PXR and CAR.** To understand the molecular mechanism by which PXR and CAR regulate Akr1b7 gene expression, we cloned the 2-kb 5′ flanking region of the mouse Akr1b7 gene by PCR. Inspection of the promoter sequences and assisted by using the web-based software NUBIScan version 2.0 (http://www.nubiscan.unibas.ch/), we have identified three candidate DR-4 (DR4-1, -2, and -3) and one DR-3 site (Fig. 3A) within 449 bp upstream of the transcription start site. After an initial screening by EMSA, we found one of the DR-4 elements, DR4-3, had a strong affinity to bind to the PXR-RXR heterodimers (Fig. 3B). The binding can be efficiently competed by unlabeled Akr1b7/DR-4 or the MDR-1/DR-4 (AGGTCAagttAGTTCA) derived from the MDR-1 gene (Geick et al., 2001), but not by two Akr1b7/DR-4 mutant variants with the DR-4 site disrupted (Fig. 3, A and B). A similar pattern of binding and competition was observed when the activated VP-PXR was used in EMSA (data not shown). The in vivo recruitment of PXR to DR4–3 was confirmed by ChIP assay. As shown in Fig. 3C, treatment of primary hepatocytes with PCN resulted in the recruitment of PXR to DR4-3. In the ChIP assay, Cd36 (a PXR target gene) (Zhou et al., 2006) and Cyp7b1 (a retinoic acid-related orphan receptor α target gene) (Wada et al., 2008) were included as positive and negative control, respectively (Fig. 3C). EMSA showed that DR4-1 and DR4-2, but not DR-3, could also bind to the PXR-RXR heterodimers (data not shown). Akr1b7/DR-4 can also specifically bind to CAR-RXR heterodimers as shown by EMSA (Fig. 3D).

Fig. 2. Activation of CAR induced the expression of Akr1b7 in vivo. A and B, real-time PCR analysis on the mRNA expression of Akr1b7 in the liver (A) and small intestine (B) of mice treated with vehicle or TCPOBOP (single intraperitoneal dose of 1 mg/kg, mice were sacrificed 7 days after injection). Cyp2b10 was included as a positive control for CAR activation. N = 5 for each group. C and D, hepatic (C) and intestinal (D) expression of Akr1b7 and Cyp2b10 was analyzed in vehicle- and TCPOBOP-treated CAR(−/−) mice. Hepatic expression of Akr1b7 mRNA in mice treated with both PCN and TCPOBOP. N = 5 for each group. **P < 0.01, compared with the vehicle groups. NS, statistically not significant (P > 0.05).
To examine the functional relevance of DR-4s in mediating the transactivation by PXR and CAR, the 2-kb 5' regulatory DNA fragment was inserted into the pGL3 basic vector to create the pGL3-Akr1b7 luciferase reporter gene. Three variant reporter genes with three DR-4s individually mutated were also generated. In transient transfection and luciferase

Fig. 3. The Akr1b7 gene promoter was activated by PXR and CAR and identification of the response element in the promoter region of Akr1b7 that binds to both PXR and CAR. A, schematic diagram of the mouse Akr1b7 gene promoter. Numbers indicate positions from the transcriptional starting site (+1). Three putative DR-4 elements and one DR-3 element are labeled. The sequences of DR4–1 and DR4–2 mutants and two DR4-3 mutants are also labeled with the mutated nucleotides underlined. B, binding of the PXR-RXR heterodimers to the radiolabeled Akr1b7/DR4-3. The arrows indicate specific shift bands. In the competition lanes, the unlabeled competitor oligonucleotides were added at 50- to 100-fold excess. Akr and MDR indicate Akr1b7/DR4-3 and MDR1/DR-4, respectively. C, recruitment of PXR to Akr1b7/DR4-3 as shown by ChIP assays. Cyp7b1 was included as the positive control of PXR target genes, respectively. D, CAR-RXR heterodimers bind to Akr1b7/DR-4. The dark and light arrows indicate specific and nonspecific shift bands, respectively. E, wild-type (WT) Akr1b7 2-kb promoter reporter gene or its DR4 mutant variants were cotransfected with the mouse PXR expression vector (pCMX-mPXr) or the mouse CAR expression vector (pCMX-mCAR) into HepG2 cells. Twelve hours after transfection, cells were treated with vehicle (DMSO), PCN (10 μM), or TCPOBOP (250 nM) for 24 h before luciferase assay. The luciferase activity was normalized against the cotransfected β-galactosidase activity. Results are shown as -fold induction over vehicle controls and represent the average and S.D. from triplicate assays.
reporter gene assay, pGL3-Akr1b7 was activated by PCN in HepG2 cells cotransfected with the expression vector for the mouse PXR (pCMX-mPXR) (Fig. 3E). It is interesting that the mutation of any of the DR-4s resulted in the loss of PXR effect (Fig. 3E). When the mouse CAR (pCMX-mCAR) was cotransfected, we found that CAR activated the wild-type report gene in the absence of an exogenously added ligand, and this activation was enhanced when TCPOBOP was added to the medium (Fig. 3E). Similarly, the mutation of any of the DR4 sites abolished the effect of CAR and TCPOBOP (Fig. 3E).

**Independent and Cooperative Regulation of Akr1b7 by PXR and LXR.** Because LXRα has been shown previously to regulate Akr1b7 via several LXR elements, including the DR-4 that binds to PXR and CAR (Volle et al., 2004), we went on to determine whether the effects of PXR and LXR on Akr1b7 gene expression are mutually dependent. As shown in Fig. 4A, PCN was effective to induce Akr1b7 mRNA expression in the liver of LXR DKO mice (Peet et al., 1998). Conversely, GW3965, an LXR agonist that does not activate PXR (Zhou et al., 2008), remained effective to induce Akr1b7 gene expression in the liver of PXR(−/−) mice (Fig. 4B). The expression of Scd-1, a known LXR target gene, was also induced in GW3965-treated PXR(−/−) mice (data not shown). These results suggest that PXR and LXR are mutually dispensable in their regulation of Akr1b7 gene expression. To determine whether PXR and LXR had an additive effect on Akr1b7 gene expression, HepG2 cells were transfected with pGL3-Akr1b7 2-kb reporter gene together with expression vectors for PXR and/or LXR. Transfected cells were then treated with PXR and/or LXR agonists for 24 h before luciferase assay. As shown in Fig. 4C, PXR and LXR apparently had an additive effect in activating the reporter gene.

**A Potential Role of PXR in Protection against Lipid Peroxidation.** Akr1b7 has been suggested to play an important role in the detoxification of lipid peroxidation products (Volle et al., 2004; Schneider et al., 2008). To determine whether PXR activation confers protection from lipid peroxidation, we analyzed lipid peroxidation in the small intestine of mice by measuring the level of MDA, a by-product of polyunsaturated fatty acid peroxidation (Frankel, 1987) and biomarker of lipid peroxidation. A significant decrease in MDA level was observed in wild-type mice treated with PCN for 76 h, compared with the vehicle-treated counterparts (Fig. 5A). The PCN effect on MDA production was abolished in PXR(−/−) mice (Fig. 5B). These results suggest that PXR plays a role in alleviating lipid peroxide accumulation in the small intestine. When the CAR effect was evaluated, we were surprised to find that treatment of TCPOBOB had little effect on the basal level of MDA in either the wild-type (Fig. 5C) or CAR(−/−) (Fig. 5D) mice.

**Discussion**

In this study, we have identified Akr1b7 as a novel target gene for the xenobiotic receptors PXR and CAR. The combined uses of pharmacologic and genetic models of PXR and CAR activation have demonstrated that activation of PXR and CAR is both necessary and sufficient for the regulation of Akr1b7 in the mouse liver and intestine. The identity of Akr1b7 as a PXR and CAR target gene was further supported by the characterization of a DR-4 response element that binds to both receptors and is required for the transactivation of Akr1b7 gene promoter. The activation of Akr1b7 gene expression by PXR and CAR has led to our appreciation that the xenobiotic receptors may have a previously unrecognized function in the detoxification of lipid peroxides.

Both RXR and LXR agonists have been shown to activate Akr1b7 gene expression. It was reported that the effect of RXR agonist LG268 on Akr1b7 gene expression was intact in LXR DKO mice (Volle et al., 2004), suggesting that RXR heterodimerization partners other than LXRs could have mediated the transactivation. Our results suggested that PXR and CAR might have mediated the activation of Akr1b7 gene expression by LG268 in LXR DKO mice. T0901317 was used by Volle et al. (2004) as the LXR agonist to induce Akr1b7 gene expression. It is interesting that the effect of T0901317 on Akr1b7 gene expression was abolished in LXRα and -β double knockout mice (Volle et al., 2004), despite the reports that T0901317 can also activate PXR (Shenoy et al., 2004).
Having demonstrated that both PXR and LXR activate Akr1b7 gene expression, an outstanding question is whether the effect of these two receptors on Akr1b7 gene expression is mutually dependent. Using mice deficient of PXR or LXRs, we showed that the PXR and LXR agonist effect on Akr1b7 gene expression was intact in LXR DKO and PXR(−/−) mice, respectively. The independent effect of PXR and LXR was further supported by our observation that PXR and LXR had an additive effect in activating the Akr1b7 gene promoter. The coregulation of Akr1b7 is reminiscent of the shared regulation of Sult2a1/2a9 by PXR (Sonoda et al., 2002), CAR (Saini et al., 2004), farnesoid X receptor (Song et al., 2001), and LXR (Uppal et al., 2007), in which an inverted repeat without a spacing nucleotide response element is used by all four receptors. We propose that the regulatory network of Akr1b7, controlled by PXR, CAR, and LXR, offers a complex and fail-safe system in preventing toxicity associated with lipid peroxidation. It remains to be determined whether the shared regulation of Akr1b7 by several nuclear receptors also contributes to the tissue distribution pattern of this AKR isofrom.

The identification of Akr1b7 as a PXR and CAR target gene has expanded the function of xenobiotic receptors in xenobiotic and endobiotic detoxification. Because AKRs functionalize carbonyl groups by forming alcohols for the conjugation reaction catalyzed by the phase II UDP-glucuronosyltransferase and sulfo transferase enzymes, they can be classified as phase I enzymes (Penning and Drury, 2007). Human AKRs have been implicated in the metabolism (carbonyl reduction) of synthetic hormones, cancer chemotherapeutics, and central nervous system-acting drugs. AKRs also play an important xenobiotic role, implicating in the detoxification of at least three classes of chemical carcinogen: polycyclic aromatic hydrocarbons, aflatoxin, and nicotine-derived nitrosamines (Penning and Drury, 2007). It remains to be determined whether the human AKRs are also regulated by xenobiotic receptors. There was no report of the human homolog of Akr1b7, AKR1B10 seemed to be the closest human relative based on the AKR family tree. Like Akr1b7, AKR1B10 is also highly expressed in the intestine and liver and functions as an aldose reductase (Cao et al., 1998). Using the human colon cancer LS180 cells overexpressing the wild-type or activated PXR (Gong et al., 2006), we showed that activation of PXR did not alter the expression of AKR1B10 (data not shown). It remains to be determined whether other human AKR isofroms can be regulated by PXR or CAR.

Although our results suggest that Akr1b7 is under the transcriptional control of both PXR and CAR, it seemed that there were differences between these two receptors in their regulation of Akr1b7. For example, the magnitude of Akr1b7 induction was higher in the intestine than that in the liver in PXR-activated mice (Fig. 1), whereas the induction was more dramatic in the liver than that in the intestine in CAR-activated mice (Fig. 2). The mechanism for this tissue effect of Akr1b7 gene regulation is currently unclear. Moreover, unlike the PXR agonist PCN that inhibited MDA formation in the intestine in a PXR-dependent manner (Fig. 5, A and B), treatment with the CAR agonist TCPOBOP failed to inhibit MDA formation (Fig. 5, C and D). The receptor-specific effect on MDA formation may have resulted from the differential effect of these two receptors on the expression of other genes, whose products might also be involved in the production and clearance of lipid peroxidation products.

The identification of Akr1b7 as a PXR target gene has also expanded the function of this receptor in lipid homeostasis. Originally identified as a “xenobiotic receptor,” PXR was later found to impact lipid homeostasis (for review, see Henschin and Meyer, 2005; Zhou et al., 2006b; Nakamura et al., 2007). The activation of PXR in the mouse liver resulted in an increased hepatic deposit of triglycerides. This PXR-mediated lipid accumulation was independent of the activation of the lipogenic transcriptional factor sterol regulatory element-binding protein 1c. Instead, the PXR-responsive lipid accumulation was associated with an increased expression of the free fatty acid transporter CD36 and several accessory lipogenic enzymes, such as stearoyl CoA desaturase-1 and long-chain free fatty acid elongase. In the same study, CD36 was established as a direct transcriptional target of PXR. Increased fatty acid uptake, such as that facilitated by CD36, may prone cells to lipid peroxidation. Indeed, an accumula-

![Fig. 5. A potential role of PXR in protection against lipid peroxidation. A and B, level of MDA in the small intestine homogenate was measured in WT (A; N = 4 for each group) or PXRN(−/−) (B; N = 3 for each group) mice treated with DMSO or PCN. Mice received four daily intraperitoneal injections of the drugs and sacrificed 4 h after the last dose, so the total treatment time is 76 h. C and D, intestinal MDA level was measured in WT (C; N = 5 for each group) or CARN−/− (D; N = 5 for each group) mice treated with DMSO or TCPOBOP. *, P < 0.05. NS, statistically not significant (P > 0.05).](https://www.molpharm.aspetjournals.org/assets/images/10.1124/mol.117.112871/figure.png)
tion of PUFAs have been proposed to be involved in the formation of atheromas in the vasculature, because PUFAs serve as substrates for lipid peroxidation (Yin and Porter, 2005). It is tempting for us to speculate that the activation of Akr1b7 by PXR may represent an evolved function for cells to protect from lipid peroxidation associated with increased fatty acid uptake. Although we have shown that activation of PXR was necessary and sufficient to decrease intestinal accumulation of the lipid peroxidation biomarker MDA, we cannot exclude the possibility that the MDA-lowering effect of PXR may have been mediated or contributed by PXR target genes other than Akr1b7. A future use of Akr1b7 null mice (Baumann et al., 2007) would further conclude that the PXR effect on the alleviation of lipid peroxidation is indeed mediated by this enzyme. Also interesting is that Akr1b7 has mouse (Baumann et al., 2007) would further conclude that the target genes other than Akr1b7. A future use of cannot excluded the possibility that the MDA-lowering effect fatty acid uptake. Although we have shown that activation of formation of atheromas in the vasculature, because PUFAs

References

Acknowledgments

We thank Dr. David Mangelsdorf for providing the LXR null mice and Dr. Ramalinga Kuruba for synthesizing GW3965.

References


Address correspondence to: Dr. Wen Xie, Center for Pharmacogenetics, 633 Salk Hall, University of Pittsburgh, Pittsburgh, PA 15261. E-mail: wxie@pitt.edu.

Downloaded from morph.usp.chem.wisc.edu on June 21, 2017 molpharm.aspetjournals.org